The Food and Drug Administration accepted the application for review for daraxonrasib on July 22, putting the experimental pancreatic cancer pill on a formal review clock.
The drug is not approved. It has been reaching patients since May through an expanded access program run by Revolution Medicines and cleared by the FDA, and that program continues while the review proceeds. More than two thousand patients in the United States are now receiving daraxonrasib, the company's chief development officer told Medscape Medical News.
For families weighing options, the practical question has shifted. It is no longer only about whether the drug can be obtained. It is what changes when a free investigational product becomes a marketed one.
The Mechanics of Expanded Access and Who Controls Them
Expanded access, also called compassionate use, lets patients with serious or life-threatening illnesses receive an investigational drug outside a clinical trial when they cannot enroll in one. It is a real pathway with real limits, and several of those limits surprise families.
A patient cannot apply. Requests must come from a physician licensed in the United States, submitted to the sponsor rather than to the FDA. The company decides whether to supply the drug, and a company is under no obligation to say yes. The FDA's role here was issuing a "safe to proceed" letter to Revolution Medicines, which the agency announced after receiving the request on April 28 and signing it two days later.
The administrative load is not trivial. Gregory Beatty of the University of Pennsylvania told Oncology News Central that the two-day turnaround was exceptionally fast and served as a test of how quickly the agency can move high-impact phase 3 data to patient access. Physicians contact the company directly, which then helps a site obtain institutional review board approval and FDA site authorization. Once a program is running, patients are registered through a portal and, if they meet eligibility criteria that mirror those of the trial, the drug arrives within days.
The cost is not zero for everyone. Revolution provides daraxonrasib at no charge, but participating sites absorb the expense of review board fees, ongoing safety monitoring, and documentation. Even so, the drug is reaching community oncology practices rather than only major academic centers, which changes the calculation for patients who cannot travel far for care.
The Trial Result Driving the Urgency
The evidence for all of this comes from RASolute 302, a global, randomized, phase 3 trial involving 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma.
Median overall survival was 13.2 months with daraxonrasib compared with 6.7 months on standard chemotherapy in the overall population, a 60 percent reduction in the risk of death. Survival figures in the subgroup with RAS G12 mutations were similar. The results were presented at the American Society of Clinical Oncology annual meeting, published simultaneously in the New England Journal of Medicine, and drew a standing ovation. Patients on the drug also reported significantly delayed deterioration in cancer-related pain and quality of life.
Daraxonrasib is a once-daily oral RAS inhibitor. Rather than blocking a mutant protein directly, it suppresses signaling between RAS proteins and their downstream effectors, an approach that allows it to address multiple mutation variants in cancers where more than 90 percent of tumors carry an oncogenic RAS mutation.
Three things deserve to be stated plainly alongside those numbers. A median of just over a year is a substantial gain in a disease where the five-year survival rate for metastatic patients sits near 3 percent, and it is not a cure. Nobody involved in the research has described it as one. And the drug carries real toxicity, with Beatty noting rash and mucositis that often require dose modifications, and responses that are usually transient.
The drug holds breakthrough therapy and orphan drug designations and was selected for the FDA Commissioner's National Priority Voucher pilot, which is designed to compress review timelines well below the usual span. The European Medicines Agency has begun a parallel phased review.
The Transition Families Should Prepare For
Approval would normally be unambiguous good news, and here it mostly is. But it changes the financial and logistical picture in ways worth anticipating.
During expanded access, the manufacturer provides the drug at no charge. After approval, the drug becomes a marketed product that must be paid for, which means insurance coverage, prior authorization, formulary placement, and out-of-pocket costs all come into play. Revolution Medicines has not disclosed pricing, and newly approved oncology drugs frequently carry substantial list prices. Coverage decisions do not arrive instantly.
The people most affected are patients with metastatic pancreatic ductal adenocarcinoma whose disease progressed after one prior regimen. Patients whose current treatment is working are generally not candidates, and oncologists have been explicit that a regimen producing benefit should not be abandoned to chase a newer option.
Practical steps for a family in this situation are narrow but concrete. Ask the treating oncologist directly whether expanded access has been requested and, if not, why. Ask whether the practice participates or whether referral is reasonable. Ask about clinical trials, which remain the preferred route when a patient is eligible, including the ongoing studies of the drug in untreated and resected disease. And ask what happens to supply and cost if approval arrives mid-treatment, because that is the question most likely to be overlooked.
What remains unknown is the action date, whether the FDA will approve it at all, the drug's cost, and how quickly insurers will cover it. MedicalDaily will report when the agency acts.
Key Questions Answered
Is daraxonrasib approved? No. The FDA accepted the new drug application for review on July 22, under a program designed to shorten the review period.
How are patients getting it now? Through an expanded access program run by Revolution Medicines and cleared by the FDA in May. More than 2,000 patients in the United States are currently receiving it.
Can a patient apply directly? No. A US-licensed physician must submit the request to the company on the patient's behalf, and the company decides.
What did the trial show? Median overall survival of 13.2 months versus 6.7 months on standard chemotherapy in the phase 3 RASolute 302 trial, which enrolled 500 patients.
Does it cure pancreatic cancer? No. It extended median survival in previously treated metastatic disease, and it carries side effects including rash and mucositis that often require dose changes.
Who is eligible? Generally, patients with previously treated metastatic pancreatic ductal adenocarcinoma who cannot enroll in a clinical trial. Patients whose current treatment is working are usually not candidates.
What changes if it is approved? The manufacturer supplies the drug free during expanded access. After approval, it becomes a purchased product subject to insurance coverage, prior authorization, and out-of-pocket costs.
